BioCentury
ARTICLE | Clinical News

Signifor LAR pasireotide regulatory update

January 26, 2015 8:00 AM UTC

FDA approved once-monthly Signifor LAR pasireotide from Novartis to treat acromegaly in patients who have had an inadequate response to surgery and/or for whom surgery is not an option. The long-acti...